Antidiabetic Rosiglitazone Reduces Soluble Intercellular Adhesion Molecule-1 Level in Type 2 Diabetic Patients with Coronary Artery Disease

Table 2

Metabolic features of patients before and 6 months after rosiglitazone treatment. Values are mean ± SD.

Metabolic parameters	Control group (𝑛=56)		Rosiglitazone group (𝑛=60)
	Baseline	after 6 months	Baseline	after 6 months
Total cholesterol, mmol/L	4.80±0.57	4.33±0.51^∗	4.85±0.48	4.27±0.42^#
High-density lipoprotein, mmol/L	1.02±0.15	1.26±0.11^#	1.04±0.12	1.35±0.15^#
Low-density lipoprotein, mmol/L	2.87±0.63	2.67±0.55	2.93±0.78	2.53±0.73^∗
Triglycerides, mmol/L	2.01±0.70	1.75±0.61	1.99±0.63	1.62±0.62
Body mass index	25.50±2.7	25.37±2.34	26.17±2.60	26.49±2.11

^*𝑃<.05 compared to baseline;
^#𝑃<.01 compared to baseline.